Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06252649 · ClinicalTrials.gov registry record · Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
A Phase 3 study of Metastatic Colorectal Cancer, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT06252649: Recruiting Phase 3 study of Metastatic Colorectal Cancer, sponsored by Amgen.
NCT06252649 is a Phase 3 study of Metastatic Colorectal Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 450 participants, above the 176-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (156% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06252649, a Phase 3 study of Metastatic Colorectal Cancer, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
Conditions Studied
Interventions
- DRUG Sotorasib
- DRUG Panitumumab
- DRUG FOLFIRI Regimen
- DRUG Bevacizumab-awwb
Study Locations (20)
California
- Providence Saint Jude Medical Center - Fullerton
- City of Hope National Medical Center - Long Beach
- Cancer and Blood Research Center, LLC - Los Alamitos
- California Research Institute - Los Angeles
Florida
- Cancer Specialists of North Florida - Southpoint - Jacksonville
- D and H Cancer Research Center - Margate
- Mid Florida Hematology and Oncology Centers PA - Orange City
- Boca Raton Clinical Research Medical Center Inc - Plantation
Illinois
- Insight Research Institute - Chicago
- Hope and Healing Cancer Services - Hinsdale
- Orchard Healthcare Research Inc - Skokie
Michigan
- Henry Ford Health System - Detroit
- Cancer and Hematology Centers of Western Michigan - Grand Rapids
Arizona
- Ironwood Cancer and Research Centers Scottsdale - Chandler
Connecticut
- Norwalk Hospital - Norwalk
Georgia
- Georgia Cancer Specialists - Atlanta
Kentucky
- Pikeville Medical Center - Pikeville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2024-07-17 |
| Est. Completion | 2031-08-31 |
| Phase | Phase 3 |
What NCT06252649 shows while recruiting
NCT06252649 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, above the 176-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (156% higher).
The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Sotorasib is the first listed.
NCT06252649 names 20 study sites across 11 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06252649 about?
NCT06252649 is a clinical study titled "Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation". The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
What is the current status of trial NCT06252649?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2024-07-17. Estimated completion is 2031-08-31.
What conditions does trial NCT06252649 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT06252649?
The interventions under investigation include: Sotorasib (DRUG), Panitumumab (DRUG), FOLFIRI Regimen (DRUG), Bevacizumab-awwb (DRUG).
Who is sponsoring clinical trial NCT06252649?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06252649 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06252649's enrollment target sits among peer trials
450 7th of 45 higher than 39 of 45 other Metastatic Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
RECRUITING · Phase 3
-
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
ACTIVE NOT RECRUITING · Phase 3
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI